{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:11:36Z","timestamp":1783973496355,"version":"3.55.0"},"reference-count":182,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic liver diseases are commonly associated with dysregulated cholesterol metabolism. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is a serine protease of the proprotein convertase family that is mainly synthetized and secreted by the liver, and represents one of the key regulators of circulating low-density lipoprotein (LDL) cholesterol levels. Its ability to bind and induce LDL-receptor degradation, in particular in the liver, increases circulating LDL-cholesterol levels in the blood. Hence, inhibition of PCSK9 has become a very potent tool for the treatment of hypercholesterolemia. Besides PCSK9 limiting entry of LDL-derived cholesterol, affecting multiple cholesterol-related functions in cells, more recent studies have associated PCSK9 with various other cellular processes, including inflammation, fatty acid metabolism, cancerogenesis and visceral adiposity. It is increasingly becoming evident that additional roles for PCSK9 beyond cholesterol homeostasis are crucial for liver physiology in health and disease, often contributing to pathophysiology. This review will summarize studies analyzing circulating and hepatic PCSK9 levels in patients with chronic liver diseases. The factors affecting PCSK9 levels in the circulation and in hepatocytes, clinically relevant studies and the pathophysiological role of PCSK9 in chronic liver injury are discussed.<\/jats:p>","DOI":"10.3390\/ijms23031070","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:20:57Z","timestamp":1642580457000},"page":"1070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-8887","authenticated-orcid":false,"given":"Thomas","family":"Grewal","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Regensburg University Hospital, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1742-4658.2008.06807.x","article-title":"SREBPs: Protein interaction and SREBPs","volume":"276","author":"Sato","year":"2009","journal-title":"FEBS J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: From Basic Science Discoveries to Clinical Trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sundararaman, S.S., Doring, Y., and van der Vorst, E.P.C. (2021). PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070793"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid Lowering Therapy and Circulating PCSK9 Concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11789-017-0085-0","article-title":"PCSK9 targets important for lipid metabolism","volume":"12","author":"Schulz","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2796.2007.01915.x","article-title":"Characterization of novel mutations in the catalytic domain of the PCSK9 gene","volume":"263","author":"Cameron","year":"2008","journal-title":"J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: Functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1194\/jlr.RA120000964","article-title":"Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9","volume":"62","author":"Oleaga","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-019-0949-3","article-title":"Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina","volume":"18","author":"Caselli","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12876-015-0371-6","article-title":"Decreased PCSK9 expression in human hepatocellular carcinoma","volume":"15","author":"Bhat","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3803\/EnM.2020.35.2.480","article-title":"Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance","volume":"35","author":"Han","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/clp.13.55","article-title":"Rapid effects of different lipid-lowering drugs on PCSK9 in humans","volume":"8","author":"Liu","year":"2013","journal-title":"Clin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0181540","DOI":"10.1371\/journal.pone.0181540","article-title":"Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease","volume":"12","author":"Schlegel","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0022-2275(20)38144-X","article-title":"Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins","volume":"23","author":"Miettinen","year":"1982","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jc.2017-00684","article-title":"The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response","volume":"102","author":"Ooi","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.14711","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12944-021-01431-x","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis","volume":"20","author":"Feder","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","article-title":"PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice","volume":"6","author":"Parhofer","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40264-020-01021-3","article-title":"PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database","volume":"44","author":"Zinzi","year":"2021","journal-title":"Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102480","DOI":"10.1016\/j.nano.2021.102480","article-title":"Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia","volume":"40","author":"Salaheldin","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12946","article-title":"Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality","volume":"286","author":"Rannikko","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOL.0b013e3283468c28","article-title":"Hepatic Niemann-Pick C1-like 1","volume":"22","author":"Pramfalk","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1194\/jlr.P900004-JLR200","article-title":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and\/or simvastatin in men","volume":"50","author":"Sudhop","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin\/kexin type 9","volume":"283","author":"Kourimate","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Grewal, T., Rentero, C., Enrich, C., Wahba, M., Raabe, C.A., and Rescher, U. (2021). Annexin Animal Models-From Fundamental Principles to Translational Research. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073439"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation","volume":"7","author":"Seidah","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2017.04.010","article-title":"Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene","volume":"261","author":"Fairoozy","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Buechler, C., Haberl, E.M., Rein-Fischboeck, L., and Aslanidis, C. (2017). Adipokines in Liver Cirrhosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071392"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/138920011794520035","article-title":"Does hepatic steatosis affect drug metabolizing enzymes in the liver?","volume":"12","author":"Buechler","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000282083","article-title":"The role of cytokines in non-alcoholic fatty liver disease","volume":"28","author":"Tilg","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"12","author":"Albillos","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","article-title":"Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice","volume":"40","author":"Garcon","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","article-title":"PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells","volume":"227","author":"Levy","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1194\/jlr.P071704","article-title":"Effect of evolocumab on cholesterol synthesis and absorption","volume":"57","author":"Peach","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1161\/ATVBAHA.118.310882","article-title":"Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism","volume":"38","author":"Chan","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: A narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"158658","DOI":"10.1016\/j.bbalip.2020.158658","article-title":"Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma","volume":"1865","author":"Buechler","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.addr.2020.06.027","article-title":"The hepatic lipidome: From basic science to clinical translation","volume":"159","author":"Pater","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ecl.2008.06.007","article-title":"Obesity and free fatty acids","volume":"37","author":"Boden","year":"2008","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1373\/clinchem.2007.100156","article-title":"The perfect storm: Obesity, adipocyte dysfunction, and metabolic consequences","volume":"54","author":"Mozaffarian","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DMSO.S115855","article-title":"Diabetes and dyslipidemia: Characterizing lipoprotein metabolism","volume":"10","author":"Tomkin","year":"2017","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MOL.0000000000000577","article-title":"Molecular regulation of plasma lipid levels during systemic inflammation and sepsis","volume":"30","author":"Trinder","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12944-016-0339-8","article-title":"Correlation between serum levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease","volume":"15","author":"Nozue","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1042\/CS20140832","article-title":"Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk","volume":"128","author":"Guardiola","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"ref_67","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.zefq.2017.04.001","article-title":"Changes in the prevalence of statin use in Germany\u2014Findings from national health interview and examination surveys 1997\u20131999 and 2008\u20132011","volume":"122","author":"Knopf","year":"2017","journal-title":"Z. Evidenz Fortbild. Qual. Gesundh."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/S0004-28032015000300011","article-title":"Lipid Profile of Cirrhotic Patients and Its Association with Prognostic Scores: A Cross-Sectional Study","volume":"52","author":"Bassani","year":"2015","journal-title":"Arq. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","article-title":"Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease","volume":"126","author":"Lonardo","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2013.03.029","article-title":"Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin\/kexin type 9 (PCSK9) deficiency","volume":"228","author":"Janis","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: Impact of sample collection methodology","volume":"51","author":"Hammad","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/ATVBAHA.115.305504","article-title":"High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease","volume":"35","author":"Agarwala","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-008-2213-6","article-title":"Adipocytokines and liver disease","volume":"43","author":"Kamada","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref_79","first-page":"2801","article-title":"Adiponectin, a key adipokine in obesity related liver diseases","volume":"17","author":"Buechler","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12967-016-1032-4","article-title":"Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: Linking dyslipidemia with obesity","volume":"14","author":"Du","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.ajpath.2020.07.016","article-title":"Leptin, Resistin, and Proprotein Convertase Subtilisin\/Kexin Type 9: The Role of STAT3","volume":"190","author":"Macchi","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2147\/DMSO.S321311","article-title":"Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication","volume":"14","author":"Dessie","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","article-title":"Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line","volume":"291","author":"Ruscica","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1194\/jlr.M010603","article-title":"Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells","volume":"52","author":"Cao","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: From physiopathology to therapy","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.29421","article-title":"Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice","volume":"67","author":"Matsuda","year":"2018","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12970\/2308-6483.2016.04.02.3","article-title":"Interleukin-1\u03b2 Regulates PCSK9 and LDL Receptor Expression together with de novo Cholesterol Synthesis in HepG2 Cells","volume":"4","author":"Nielsen","year":"2016","journal-title":"Glob. J. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e000765","DOI":"10.1136\/openhrt-2017-000765","article-title":"Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction","volume":"5","author":"Ueland","year":"2018","journal-title":"Open Heart"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/ATVBAHA.117.309630","article-title":"Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin\/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice","volume":"37","author":"Sun","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: A review of experimental and clinical evidence","volume":"5","author":"Gotto","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/kjm2.12225","article-title":"Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4\/nuclear factor-kappa B","volume":"36","author":"Lei","year":"2020","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J. Innate. Immun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0210808","DOI":"10.1371\/journal.pone.0210808","article-title":"PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort","volume":"14","author":"Mitchell","year":"2019","journal-title":"PLoS ONE"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.30506","article-title":"The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis","volume":"70","author":"Cai","year":"2019","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cld.2008.07.002","article-title":"Immune interactions in hepatic fibrosis","volume":"12","author":"Holt","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/liv.14993","article-title":"Proprotein convertase subtilisin\/kexin type 9 regulates the production of acute-phase reactants from the liver","volume":"41","author":"Saralahti","year":"2021","journal-title":"Liver Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cld.2017.08.014","article-title":"Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma","volume":"22","author":"Massoud","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467208666150817111419","article-title":"The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver","volume":"10","author":"Clugston","year":"2017","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jgh.12030","article-title":"Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy","volume":"28","author":"Orman","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/hep.510270601","article-title":"Hepatic steatosis: Innocent bystander or guilty party?","volume":"27","author":"Day","year":"1998","journal-title":"Hepatology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0741-8329(97)00133-X","article-title":"Ethanol enhances cholesterol synthesis and secretion in human hepatomal cells","volume":"15","author":"Visioli","year":"1998","journal-title":"Alcohol"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fimmu.2016.00538","article-title":"Critical Roles of Kupffer Cells in the Pathogenesis of Alcoholic Liver Disease: From Basic Science to Clinical Trials","volume":"7","author":"Zeng","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hep.24524","article-title":"Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice","volume":"54","author":"Louvet","year":"2011","journal-title":"Hepatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.26607","article-title":"M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease","volume":"59","author":"Wan","year":"2014","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/mp.2017.168","article-title":"Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder","volume":"23","author":"Lohoff","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in decompensated cirrhosis: New concepts and perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.3748\/wjg.v24.i47.5297","article-title":"Hepatitis C: From inflammatory pathogenesis to anti-inflammatory\/hepatoprotective therapy","volume":"24","author":"Li","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3748\/wjg.v22.i6.1953","article-title":"Hepatitis C virus relies on lipoproteins for its life cycle","volume":"22","author":"Grassi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1099\/jgv.0.000987","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A","volume":"99","author":"Li","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.08.020","article-title":"Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin\/Kexin Type 9","volume":"23","author":"Hyrina","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e0154498","DOI":"10.1371\/journal.pone.0154498","article-title":"Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes","volume":"11","author":"Ramanathan","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Zapatero-Belinchon, F.J., Otjengerdes, R., Sheldon, J., Schulte, B., Carriqui-Madronal, B., Brogden, G., Arroyo-Fernandez, L.M., Vondran FW, R., Maasoumy, B., and von Hahn, T. (2021). Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells, 10.","DOI":"10.3390\/cells10071626"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1128\/JVI.02727-13","article-title":"Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation","volume":"88","author":"Syed","year":"2014","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Fasolato, S., Pigozzo, S., Pontisso, P., Angeli, P., Ruscica, M., Savarino, E., De Martin, S., Lupo, M.G., and Ferri, N. (2020). PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103134"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1002\/hsr2.273","article-title":"Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin\/kexin type 9 level","volume":"4","author":"Torti","year":"2021","journal-title":"Health Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","article-title":"PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism","volume":"62","author":"Bridge","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_128","first-page":"156","article-title":"Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir\/Asunaprevir","volume":"10","author":"Ichikawa","year":"2019","journal-title":"Biomed. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Grimm, J., Peschel, G., M\u00fcller, M., Schacherer, D., Wiest, R., Weigand, K., and Buechler, C. (2021). Rapid Decline of Serum Proprotein Convertase Subtilisin\/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081621"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e002683","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent \u201cPCSK9-Lipid Paradox\u201d","volume":"5","author":"Kohli","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Graf, C., Welzel, T., Bogdanou, D., Vermehren, J., Beckel, A., Bojunga, J., Friedrich-Rust, M., Dietz, J., Kubesch, A., and Mondorf, A. (2020). Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092702"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e0163644","DOI":"10.1371\/journal.pone.0163644","article-title":"Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment","volume":"11","author":"Hashimoto","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/atm-20-669","article-title":"Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment","volume":"9","author":"Iossa","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.3748\/wjg.v22.i46.10226","article-title":"Genotype specific peripheral lipid profile changes with hepatitis C therapy","volume":"22","author":"Pedersen","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Peschel, G., Grimm, J., Gulow, K., Muller, M., Buechler, C., and Weigand, K. (2020). Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics, 10.","DOI":"10.3390\/diagnostics10110974"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00261-019-02031-1","article-title":"Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: Single-center experience","volume":"44","author":"Alem","year":"2019","journal-title":"Abdom. Radiol. (N. Y.)"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). Electronic address e. e. e. EASL-ALEH Clinical Practice Guidelines: Non-invasive testsfor evaluation of liver disease severity and prognosis. J. Hepatol., 63, 237\u2013265.","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4254\/wjh.v9.i8.436","article-title":"Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis C","volume":"9","author":"Andrade","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cmi.2016.09.017","article-title":"Role of assessing liver fibrosis in management of chronic hepatitis C virus infection","volume":"22","author":"Carmona","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological features of fatty liver disease","volume":"147","author":"Yeh","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The Role of Cholesterol in the Pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e141513","DOI":"10.1172\/JCI141513","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","volume":"131","author":"He","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbadis.2014.02.012","article-title":"Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH)","volume":"1842","author":"Jha","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbalip.2014.08.015","article-title":"Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet","volume":"1841","author":"Tanaka","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000282097","article-title":"Animal models of non-alcoholic steatohepatitis: Of mice and man","volume":"28","author":"Schattenberg","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Ioannou, G.N., Lee, S.P., Linsley, P.S., Gersuk, V., Yeh, M.M., Chen, Y.Y., Peng, Y.J., Dutta, M., Mascarinas, G., and Molla, B. (2021). Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatol. Commun.","DOI":"10.1002\/hep4.1858"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_154","unstructured":"Dimakopoulou, A., Sfikas, G., and Athyros, V. (2018). PCSK9 administration ameliorates nonalcoholic fatty disease in patients with heterozygous familial hyperlipidemia. Hell. J. Atheroscler., 9."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e128650","DOI":"10.1172\/JCI128650","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury","volume":"131","author":"Lebeau","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jacl.2020.12.010","article-title":"Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD","volume":"15","author":"Gawrieh","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","article-title":"Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population","volume":"278","author":"Wargny","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"158792","DOI":"10.1016\/j.bbalip.2020.158792","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","article-title":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","volume":"77","author":"Paquette","year":"2020","journal-title":"Clin. Biochem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/hep.27224","article-title":"Hepatitis B virus: The \u201cmetabolovirus\u201d highjacks cholesterol and bile acid metabolism","volume":"60","author":"Geier","year":"2014","journal-title":"Hepatology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e1009722","DOI":"10.1371\/journal.ppat.1009722","article-title":"Human low-density lipoprotein receptor plays an important role in hepatitis B virus infection","volume":"17","author":"Li","year":"2021","journal-title":"PLoS Pathog."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacl.2016.05.004","article-title":"Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report","volume":"10","author":"Nagashima","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2013.05.030","article-title":"The metabolomic window into hepatobiliary disease","volume":"59","author":"Beyoglu","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-021-00218-1","article-title":"PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14728222.2019.1615883","article-title":"Aberrant lipid metabolism as a therapeutic target in liver cancer","volume":"23","author":"Pope","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2021.0368","article-title":"Protein convertase subtilisin\/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway","volume":"18","author":"He","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_170","unstructured":"(2019, December 19). Proteinatlas The Human Protein Atlas. Available online: https:\/\/www.proteinatlas.org."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"111758","DOI":"10.1016\/j.biopha.2021.111758","article-title":"PCSK9 and cancer: Rethinking the link","volume":"140","author":"Mahboobnia","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.1421601112","article-title":"Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma","volume":"112","author":"Guillaumond","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/19336918.2015.1019996","article-title":"The cross-talk of LDL-cholesterol with cell motility: Insights from the Niemann Pick Type C1 mutation and altered integrin trafficking","volume":"9","author":"Hoque","year":"2015","journal-title":"Cell Adh. Migr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1139\/o79-073","article-title":"Low density lipoprotein binding, internalization, and degradation in human adipose cells","volume":"57","author":"Angel","year":"1979","journal-title":"Can. J. Biochem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/bst0320103","article-title":"Adipocyte cholesterol balance in obesity","volume":"32","author":"Ferre","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7555\/JBR.34.20190124","article-title":"LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: A focus on white adipose tissue","volume":"34","author":"Faraj","year":"2020","journal-title":"J. Biomed. Res."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Bordicchia, M., Spannella, F., Ferretti, G., Bacchetti, T., Vignini, A., Di Pentima, C., Mazzanti, L., and Sarzani, R. (2019). PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020245"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"32523","DOI":"10.1074\/jbc.M003826200","article-title":"Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice","volume":"275","author":"Coburn","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"212562","DOI":"10.7573\/dic.212562","article-title":"Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus","volume":"7","author":"Kosmas","year":"2018","journal-title":"Drugs Context"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.2337\/db19-1134","article-title":"Phenotypic and Genetic Characterization of Lower LDL Cholesterol and Increased Type 2 Diabetes Risk in the UK Biobank","volume":"69","author":"Klimentidis","year":"2020","journal-title":"Diabetes"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e14721","DOI":"10.14814\/phy2.14721","article-title":"Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome","volume":"9","author":"Cyr","year":"2021","journal-title":"Physiol. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yexmp.2013.10.002","article-title":"LDL but not HDL increases adiponectin release of primary human adipocytes","volume":"95","author":"Krautbauer","year":"2013","journal-title":"Exp. Mol. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:04:02Z","timestamp":1760133842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":182,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031070"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031070","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}